Brief: Brainstorm Cell Therapeutics Announces Peer-Reviewed Publication Of Biomarker Data From NurOwn's Phase 3 Clinical Trial In ALS
10/04/2024 11:11
April 10 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS ANNOUNCES PEER-REVIEWED
PUBLICATION
OF BIOMARKER DATA FROM NUROWN'S® PHASE 3 CLINICAL TRIAL IN ALS
* BRAINSTORM CELL THERAPEUTICS INC: NUROWN TREATMENT
RESULTED IN A
POSITIVE IMPACT ON IMPORTANT CSF BIOMARKERS RELEVANT TO ALS
COMPARED TO PLACEBO
Source text for Eikon: ID:nPn6Xz16Ga
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview